Press Releases

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new initiative with Servier. The two partners will implement BioMed X’s proven XSeed Labs incubator model at Servier’s research and development site in Paris-Saclay. This new XSeed Labs – the first of its kind in Europe – will be hosted at the Spartners incubator facility which is operated by BioLabs. XSeed Labs is an adaptation of BioMed X’s uniqu

Longeveron Inc, a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy (DCM). The accepted IND application provides for moving directly to a single Phase 2 pivotal registratio

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for SCG101V, marking the first-ever investigational cell therapy to enter regulatory approved Phase 1/2 clinical trial for chronic hepatitis B virus (HBV) infection. SCG101 is designed to cure chronic

NYB.AI and Pnaseer Inc. (Pnaseer) have announced a strategic partnership to accelerate the discovery of compounds that promote hair follicle regeneration using artificial intelligence (AI). The collaboration combines NYB.AI’s AI-powered compound screening capabilities with Pnaseer’s proprietary bio-nanoparticle drug delivery platform to enhance therapeutic efficacy. NYB.AI’s CEO, Giang Nguyen, and Pnaseer’s Global Business Development Director, Dr Shin Sung M

HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal mapping of the genome for target discovery with HeartBeat.bio’s human-based Cardioid Drug Discovery Platform to drive innovation in heart failure drug development. Under the agreement, biotx.ai will apply its large-scale Mendelian randomization platform to discover previously unrecogni

Akeso, Inc. has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispecific ADC to enter clinical trials. AK146D1 has recently received approval from the U.S. FDA, Australia's TGA, and China's NMPA to begin clinical trials. Currently, Akeso's globally first-in-class bispecific antibodies, cadonilimab (PD-1

Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) is a clinical-stage cell therapy company headquartered in Hsinchu, Taiwan, advancing mesenchymal stem cell (MSCs) therapies. Leveraging its patented technologies, the company's platform provides safer and potent therapies with solid evidence, which there are four stem cell therapy products have been verified by human clinical trials, and two of them have progressed toward phase III. In addition, the one targeting chronic stroke, G

Neurizon Therapeutics Limited a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon’s lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in

ValGenesis, Inc., the global leader in digital validation lifecycle management, today announced a strategic partnership with CAI, a professional services firm specializing in accelerating operational readiness in mission-critical environments, to expand the use of artificial intelligence (AI) in life sciences validation. Through the partnership, CAI will deliver implementation services for ValGenesis’ AI-enabled platform, helping life sciences companies modernize their validat

Corporate Learning Network is proud to announce the return of the CLO Exchange: Healthcare & Life Sciences, taking place September 10–12, 2025, at the iconic Merck campus in Greater Philadelphia. This invitation-only, executive-level gathering will unite senior Learning & Development leaders across healthcare systems, biotech, pharma, and medical device industries to address critical workforce challenges and transformative learning strategies. World-Class Venue